The effect of IFN-β on black holes in patients with multiple sclerosis

Expert Opinion on Biological Therapy

Volumn 7, Issue 7, 2007, Pages 1079-1091

  Bagnato, Francesca ^a   Evangelou, Iordanis E ^a   Gallo, Antonio ^a   Gaindh, Deeya ^a   Yao, Karen ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Black holes; IFN ; Magnetic resonance imaging; Multiple sclerosis; T1 hypointensities

Indexed keywords

BETA INTERFERON; INTERFERON BETA SERINE; PLACEBO;

ARTICLE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; BRAIN; GLIA; IMAGE ENHANCEMENT; PATHOLOGY; REVIEW;

BRAIN; HUMANS; IMAGE ENHANCEMENT; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEUROGLIA;

EID: 34547627505     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.7.1079     Document Type: Article

References (60)

1. 1b in the treatment of multiple sclerosis. Expert Opin. Pharmacother. (2005) 6(16):2877-2886.
2. MCFARLAND HF: The emerging role of MRI in multiple sclerosis and the new diagnostic criteria. Mult. Scler. (2002) 8(1):71-72.
3. BARKHOF F, KARAS GB, VAN WALDERVEEN MA: T1 hypointensities and axonal loss. Neuroimaging Clin. N. Am. (2000) 10(4):739-752.
4. TRUYEN L, VAN WAESBERGHE JH, VAN WALDERVEEN MA et al.: Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology (1996) 47(6):1469-1476.
5. BARKHOF F, MCGOWAN JC, VAN WAESBERGHE JH, GROSSMAN RI: Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. J. Neurol. Neurosurg. Psychiatry (1998) 64(Suppl. 1):S77-S79. •• This paper underlined the historical origin of BHs and their theoretical explanation. Further, unresolved issues of BHs are discussed.
6. BARKHOF F, VAN WALDERVEEN M: Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. Philos. Trans. R. Soc. Lond. B Biol. Sci. (1999) 354(1390):1675-1686. • This paper provided a complete coverage of the MRI characterisation of tissue damage and an attempt to address the clinico-radiological paradox is made.
7. DHIB-JALBUT S: Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology (2002) 58(8 Suppl. 4):S3-S9.
8. 1b (Betaferon) in multiple sclerosis. J. Neurol. (2005) 252(Suppl. 3):iii28-iii33.
9. KIESEIER BC, HARTUNG HP: Interferon-β and neuroprotection in multiple sclerosis-facts, hopes and phantasies. Exp. Neurol. (2007) 203(1):1-4.
10. 1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images. J. Neurol. Neurosurg. Psychiatry (1999) 67(5):579-584.
11. 1a. Multiple Sclerosis Collaborative Research Group. Neurology (2000) 55(2):185-192.
12. 1b treatment. Brain (2001) 124(Part 7):1396-1402.
13. 1b on the evolution of enhancing lesions in secondary progressive MS. Neurology (2001) 57(12):2185-2190.
14. PAOLILLO A, POZZILLI C, GIUGNI E et al.: A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-β. Eur. J. Neurol. (2002) 9(6):645-655.
15. 1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch. Neurol. (2005) 62(11):1684-1688.
16. WEISHAUPT D, KOECHLI VD, MARINCEK B: How does MRI work?: An Introduction to the Physics and Function of Magnetic Resonance Imaging. Springer-Verlag, New York, USA (2003):138.
17. FILIPPI M, HORSFIELD MA, TOFTS PS et al.: Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain (1995) 118(Part 6):1601-1612.
18. MILLER DH: Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann. Neurol. (1994) 36(Suppl.):S91-S94.
19. UHLENBROCK D, SEHLEN S: The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE). Neuroradiology (1989) 31(3):203-212.
20. BARKHOF F, BRUCK W DE GROOT CJ et al.: Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch. Neurol. (2003) 60(8):1073-1081.
21. BITSCH A, KUHLMANN T, STADELMANN C et al.: A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann. Neurol. (2001) 49(6):793-796.
22. VAN WAESBERGHE JH, KAMPHORST W, DE GROOT CJ et al.: Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann. Neurol. (1999) 46(5):747-754.
23. VAN WALDERVEEN MA, KAMPHORST W, SCHELTENS P et al.: Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 50(5):1282-1288.
24. HIEHLE JF Jr, GROSSMAN RI, RAMER KN, GONZALEZ-SCARANO F, COHEN JA: Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. Am. J. Neuroradiol. (1995) 16(1):69-77.
25. HIEHLE JF JR, LENKINSKI RE, GROSSMAN RI et al.: Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn. Reson. Med. (1994) 32(3):285-293.
26. LOEVNER LA, GROSSMAN RI, MCGOWAN JC, RAMER KN, COHEN JA: Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. Am. J. Neuroradiol. (1995) 16(7):1473- 1479.
27. BITSCH A, BRUHN H, VOUGIOUKAS V et al.: Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am. J. Neuroradiol. (1999) 20(9):1619- 1627.
28. VAN WALDERVEEN MA, TRUYEN L, VAN OOSTEN BW et al.: Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. Arch. Neurol. (1999) 56(3):345-351.
29. BARKER GJ, SCHREIBER WG, GASS A et al.: A standardised method for measuring magnetisation transfer ratio on MR imagers from different manufacturers - the EuroMT sequence. MAGMA (2005) 18(2):76-80.
30. VAN WAESBERGHE JH, VAN WALDERVEEN MA, CASTELIJNS JA et al.: Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am. J. Neuroradiol. (1998) 19(4):675-683.
31. CICCARELLI O, GIUGNI E, PAOLILLO A et al.: Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur. J. Neurol. (1999) 6(4):455-459.
32. BAGNATO F, JEFFRIES N, RICHERT ND et al.: Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain (2003) 126(Part 8):1782-1789.
33. VAN WALDERVEEN MA, BARKHOF F, HOMMES OR et al.: Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology (1995) 45(9):1684-1690.
34. FREITAG P, MUELLER B, RADUE EW, KAPPOS L: Individual changes of chronic black holes. 17th Congress of the sEuropean Commitee for Treatment and Research in Multiple Sclerosis. Dublin, Ireland, UK (2001) (Abstract).
35. SAILER M, LOSSEFF NA, WANG L et al.: T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur. J. Neurol. (2001) 8(1):37-42.
36. BAGNATO F, FRANK JA: The role of nonconventional magnetic resonance imaging techniques in demyelinating disorders. Curr. Neurol. Neurosci. Rep. (2003) 3(3):238-245.
37. LUCCHINETTI CF, BRUCK W, LASSMANN H: Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol. (2004) 56(2):308.
38. ROVIRA A, ALONSO J, CUCURELLA G et al.: Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. Am. J. Neuroradiol. (1999) 20(10):1939-1945.
39. TRAPP BD, PETERSON J, RANSOHOFF RM et al.: Axonal transection in the lesions of multiple sclerosis. N. Eng. J. Med. (1998) 338(5):278-285.
40. KOIKE F, SATOH J, MIYAKE S et al.: Microarray analysis identifies interferon β-regulated genes in multiple sclerosis. J. Neuroimmunol. (2003) 139(1-2):109-118.
41. WEINSTOCK-GUTTMAN B, HONG J, SANTOS R et al.: Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult. Scler. (2006) 12(5):541-550.
42. 1b therapy. J. Clin. Invest. (1997) 99(11):2664-2671.
43. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. (2004) 199(7):971-979.
44. ASTIER AL, MEIFFREN G, FREEMAN S, HAFLER DA: Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. (2006) 116(12):3252-3257.
45. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. (2006) 212:8-27.
46. + regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J. Neuroimmunol. (2007) 182(1-2):204-211.
47. YONG VW, CHABOT S, STUVE O, WILLIAMS G: Interferon-β in the treatment of multiple sclerosis: mechanisms of action. Neurology (1998) 51(3):682-689.
48. CALABRESI PA, TRANQUILL LR, DAMBROSIA JM et al.: Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann. Neurol. (1997) 41(5):669-674.
49. MURARO PA, LEIST T, BIELEKOVA B, MCFARLAND HF: VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis. J. Neuroimmunol. (2000) 111(1-2):186-194.
50. TEIGE I, LIU Y, ISSAZADEH-NAVIKAS S: IFN-β inhibits T cell activation capacity of central nervous system APCs. J. Immunol. (2006) 177(6):3542-3553.
51. 1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS. Neurology (2000) 55(10):1497-1505.
52. BIERNACKI K, ANTEL JP, BLAIN M et al.: Interferon-β promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. (2005) 62(4):563-568.
53. TEIGE I, TRESCHOW A, TEIGE A et al.: IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. (2003) 170(9):4776-4784.
54. 1a on neuronal survival under autoimmune inflammatory conditions. Exp. Neurol. (2006) 201(1):172-181. • An intriguing study using a rat model that experimentally demonstrated a potential neuroprotective effect of IFN-β in autoimmune inflammatory conditions.
55. RANSOHOFF RM, TREBST C: Surprising pleiotropy of nerve growth factor in the treatment of experimental autoimmune encephalomyelitis. J. Exp. Med (2000) 191(10):1625-1630. • An interesting discussion on the mechanisms of NGF and implications in experimental animal models of neurodegenerative diseases.
56. FLUGEL A, MATSUMURO K, NEUMANN H et al.: Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur. J. Immunol. (2001) 31(1):11-22.
57. 1a. J. Neurol. (1999) 246(6):443-448.
58. BAGNATO F, JEFFRIES N, RICHERT N et al.: Interferon-β therapy does not affect duration in time of Gd-enhancing lesions and black holes in relapsing remitting multiple sclerosis. American Academy of Neurology (AAN), 55th Annual Meeting. Honolulu, HI, USA (2003) (Abstract).
59. 1a in two relapsing-remitting multiple sclerosis studies. 22nd Congress of the European Commitee for Treatment and Research in Multiple Sclerosis. Madrid, Spain (2006).
60. CADAVID D, GÓMEZ-CHOCO M, ALEMANY M et al.: Outcome of T1-hypodensities in patients with early forms of multiple sclerosis randomised to betaseron or copaxone and followed prospectively by monthly 3T MRI for up to 2 years: preliminary analysis of the BECOME study. 22nd Congress of the European Commitee for Treatment and Research in Multiple Sclerosis. Madrid, Spain (2006) (Abstract).